Related content

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

By Lindenburg C.E.A.   Stolte I.   Langendam M.W.   Miedema F.   Williams I.G.   Colebunders R.   Weber J.N.   Fisher M.   Coutinho R.A.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2343-2347

Elsevier

Access to resources Recommend Favorite

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

By Weber J.   Cheinsong-Popov R.   Callow D.   Adams S.   Patou G.   Hodgkin K.   Martin S.   Gotch F.   Kingsman A.  

Vaccine, Vol. 13, Iss. 9, 1995-06 ,pp. : 831-834

Elsevier

Access to resources Recommend Favorite

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

By Bertolotti-Ciarlet A.   Ciarlet M.   Crawford S.E.   Conner M.E.   Estes M.K.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3885-3900

Elsevier

Access to resources Recommend Favorite

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines

By Da Silva D.M.   Schiller J.T.   Kast W.M.  

Vaccine, Vol. 21, Iss. 23, 2003-07 ,pp. : 3219-3227

Elsevier

Access to resources Recommend Favorite

Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles

By Jiang B.   Estes M.K.   Barone C.   Barniak V.   O'Neal C.M.   Ottaiano A.   Madore H.P.   Conner M.E.  

Vaccine, Vol. 17, Iss. 7, 1999-02 ,pp. : 1005-1013

Elsevier

Access to resources Recommend Favorite